Study: NCT06548841

Intervention type: OTHER
Intervention: Nanobiotechnology platforms
Description: The analyses will be carried out using the novel devices, which are of two types:~1. The first type of nanobiotechnological platform encompasses the hybridization of pathogen nucleic acids - that may be present in the clinical specimen - by employing specific molecular probes.~2. The second type of nanobiotechnological platform encompasses the use of capture bacteriophages or bait Phages to specifically detect bacterial or protozoan cell surface antigens (in the case of P. aeruginosa or L. infantum respectively) or viral particles (in the case of SARS-CoV2) and the use of reporter bacteriophages (transducer Phages) for the transduction of the electrochemiluminescent signal.

Intervention type: OTHER
Intervention: Nanobiotechnology platforms
Description: The analyses will be carried out using the novel devices, which are of two types:~1. The first type of nanobiotechnological platform encompasses the hybridization of pathogen nucleic acids - that may be present in the clinical specimen - by employing specific molecular probes.~2. The second type of nanobiotechnological platform encompasses the use of capture bacteriophages or bait Phages to specifically detect bacterial or protozoan cell surface antigens (in the case of P. aeruginosa or L. infantum respectively) or viral particles (in the case of SARS-CoV2) and the use of reporter bacteriophages (transducer Phages) for the transduction of the electrochemiluminescent signal.

Intervention type: OTHER
Intervention: Nanobiotechnology platforms
Description: The analyses will be carried out using the novel devices, which are of two types:~1. The first type of nanobiotechnological platform encompasses the hybridization of pathogen nucleic acids - that may be present in the clinical specimen - by employing specific molecular probes.~2. The second type of nanobiotechnological platform encompasses the use of capture bacteriophages or bait Phages to specifically detect bacterial or protozoan cell surface antigens (in the case of P. aeruginosa or L. infantum respectively) or viral particles (in the case of SARS-CoV2) and the use of reporter bacteriophages (transducer Phages) for the transduction of the electrochemiluminescent signal.

Intervention type: OTHER
Intervention: Nanobiotechnology platforms
Description: The analyses will be carried out using the novel devices, which are of two types:~1. The first type of nanobiotechnological platform encompasses the hybridization of pathogen nucleic acids - that may be present in the clinical specimen - by employing specific molecular probes.~2. The second type of nanobiotechnological platform encompasses the use of capture bacteriophages or bait Phages to specifically detect bacterial or protozoan cell surface antigens (in the case of P. aeruginosa or L. infantum respectively) or viral particles (in the case of SARS-CoV2) and the use of reporter bacteriophages (transducer Phages) for the transduction of the electrochemiluminescent signal.

Intervention type: OTHER
Intervention: Nanobiotechnology platforms
Description: The analyses will be carried out using the novel devices, which are of two types:~1. The first type of nanobiotechnological platform encompasses the hybridization of pathogen nucleic acids - that may be present in the clinical specimen - by employing specific molecular probes.~2. The second type of nanobiotechnological platform encompasses the use of capture bacteriophages or bait Phages to specifically detect bacterial or protozoan cell surface antigens (in the case of P. aeruginosa or L. infantum respectively) or viral particles (in the case of SARS-CoV2) and the use of reporter bacteriophages (transducer Phages) for the transduction of the electrochemiluminescent signal.

Intervention type: OTHER
Intervention: Nanobiotechnology platforms
Description: The analyses will be carried out using the novel devices, which are of two types:~1. The first type of nanobiotechnological platform encompasses the hybridization of pathogen nucleic acids - that may be present in the clinical specimen - by employing specific molecular probes.~2. The second type of nanobiotechnological platform encompasses the use of capture bacteriophages or bait Phages to specifically detect bacterial or protozoan cell surface antigens (in the case of P. aeruginosa or L. infantum respectively) or viral particles (in the case of SARS-CoV2) and the use of reporter bacteriophages (transducer Phages) for the transduction of the electrochemiluminescent signal.